Do caregivers' experiences correspond with the concerns raised in the literature? Ethical issues relating to anti-dementia drugs

International Journal of Geriatric Psychiatry

Volumn 21, Issue 9, 2006, Pages 869-875

  Huizing, Anna R ^a   Berghmans, Ron L P ^a   Widdershoven, Guy A M ^a   Verhey, Frans R J ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Ethics

Indexed keywords

CHOLINESTERASE INHIBITOR; NOOTROPIC AGENT;

AGED; ARTICLE; AWARENESS; CAREGIVER; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DRUG USE; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL LITERATURE; MEDICAL PRACTICE; PATIENT CARE; QUALITATIVE ANALYSIS; SEMI STRUCTURED INTERVIEW; TREATMENT WITHDRAWAL; WORK EXPERIENCE;

AGED; ALZHEIMER DISEASE; ATTITUDE TO HEALTH; CAREGIVERS; CHOLINESTERASE INHIBITORS; DECISION MAKING; EARLY DIAGNOSIS; ETHICS, CLINICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYLCARBAMATES; PSYCHIATRIC STATUS RATING SCALES; THIRD-PARTY CONSENT; WITHHOLDING TREATMENT;

EID: 33749370455     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1576     Document Type: Article

References (28)

1. Berghmans RLP. 2000. Anti-Alzheimermiddelen: ethische aspecten van research en praktijk. [Anti-dementia drugs: ethical aspects of research and practice] Tijdschr Gerontol Geriat 31: 100-106.
2. Berghmans RLP, Dickenson DL, Ter Meulen RHJ. 2004. Mental capacity. In search of alternative perspectives. Health Care Analysis 12: 251-263.
3. Bullock R. 2002. New drugs for Alzheimer's disease and other dementias. Br J Psychiatry 180: 135-139.
4. Burns A, Russell E, Page S. 1999. New drugs for Alzheimer's disease. Br J Psychiatry 174: 476-479.
5. Clafferty RA, Brown KW, McCabe E. 1998. Under half of psychiatrists tell patients their diagnosis of Alzheimer's disease. BMJ 317(7158): 603.
6. Drickamer MA, Lachs MS. 1992. Should patients with Alzheimer's disease be told their diagnosis? N Engl J Med 326: 947-951.
7. Farlow MR, Evans RM. 1998. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 51 (Suppl.1): S36-S44.
8. Filley CM, Chapman MM, Dubovsky SL. 1996. Ethical concerns in the use of palliative drug treatment for Alzheimer's disease. J Neuropsychiat Clin Neurosci 8: 202-205.
9. Fried E. 2001. The therapeutic misconception, beneficence, and respect. Account Res 8: 331-348.
10. Haddad AM. 2004. Drugs and dementia. Pharmacotherapy and decision making by primary caregivers. In: Ethical Foundations of Palliative Care for Alzheimer Disease, Purtilo RB, Ten Have HAMJ (eds). The Johns Hopkins University Press: Baltimore, MD; 330-342.
11. Hirschman KB, Joyce CM, James BD, Xie SX, Casarett DJ, Karlawish JH. 2005. Would caregivers of Alzheimer disease patients involve their relative in a decision to use an AD-slowing medication? Am J Geriatr Psychiatry 13(11): 1014-1021.
12. Holden M, Kelly C. 2002. Use of cholinesterase inhibitors in dementia. Adv Psychiat Treatment 8: 89-96.
13. Hughes J. 2000. Ethics and the anti-dementia drugs. Int J Geriatr Psychiat 15: 538-543.
14. Karlawish JH, Klocinski JL, Merz J, Clark CM, Asch DA. 2000. Caregivers' preferences for the treatment of patients with Alzheimer's disease. Neurology 55(7): 1008-1014.
15. Karlawish JH, Casarett D, Propert KJ, James BD, Clark CM. 2002. Relationship between Alzheimer's disease severity and patient participation in decisions about their medical care. J Geriatr Psychiatry Neurol 15(2): 68-72.
16. Kelly CA, Harvey RJ, Cayton H. 1997. Drug treatments for Alzheimer's disease raise clinical and ethical problems. Br Med J 314: 693-694.
17. Marksteiner J, Schmidt R. 2004. Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions. Drugs Aging 21: 415-426.
18. Moye J, Karel MJ, Azar AR, Gurrera RJ. 2004. Capacity to consent to treatment: empirical comparison of three instruments in older adults with and without dementia. Gerontologist 44: 166-175.
19. Pinner G. 2000. Truth-telling and the diagnosis of dementia. Br J Psychiat 176: 514-515.
20. Polit DF, Hungler BP. 1995. Nursing Research. Principles and Methods. J.B. Lippincott Company: Philadelphia, PA.
21. Post SG. 1995. Dementia in our midst: the moral community. Cambr Q Healthcare Ethics 4: 142-147.
22. Post SG. 1997. Slowing the progression of Alzheimer disease: ethical issues. Alzheimer Dis Assoc Disord 11 (Suppl 5):S34-S36.
23. Post SG. 1999. Future scenarios for the prevention and delay of Alzheimer disease onset in high-risk groups. Am J Prev Med 16: 105-110.
24. Post SG, Whitehouse PJ. 1998. Emerging antidementia drugs: a preliminary ethical view. J Am Geriatr Soc 46: 784-787.
25. Post SG, Stuckey JC, Whitehouse PJ, et al. 2001. A focus group on cognition-enhancing medications in Alzheimer disease: disparities between professionals and consumers. Alzheimer Dis Assoc Disord 15: 80-88.
26. Rockwood K, Joffres C. 2002. Improving clinical descriptions to understand the effects of dementia treatment: consensus recommendations. Int J Geriatr Psychiatry 17(11): 1006-1011.
27. Shua-Haim JR, Comsti E, Shua-Haim V, Ross JS. 1997. Donepezil Aricept: the caregivers voice and clinical impression. Am J Alzheimer's Dis 12: 272-279.
28. Strauss A, Corbin J. 1998. Basics of Qualitative Research. Techniques and Procedures for Developing Grounded Theory, 2nd edn. Sage Publication: Thousand Oaks, CA.